Back

Opportunistic aldosterone testing during hypokalemia as an alternative confirmatory test for primary aldosteronism

28 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Aldosterone and hypertension Secondary Hypertension ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Miss Krishaa L

Singapore (Singapore)

5 More presentations in this session

Presentation thumbnail
Impact of hyperaldosteronism in adults with hypertension: effects on long term risk of cardiovascular disease and all cause death
Mr A. Angelico-Goncalves (Vila Nova de Gaia, PT)
Abstract Slides
Presentation thumbnail
Metabolic and inflammatory phenotypic divergence between primary aldosteronism and essential hypertension: a propensity score-matched cohort study
Professor T. Liu (Tianjin, CN)
Abstract Slides
Presentation thumbnail
Efficacy and safety of baxdrostat in resistant and uncontrolled hypertension: a systematic review and meta-analysis of randomised controlled trials
Ms J. Ferraz De Sousa (BR)
Presentation thumbnail
Eplerenone vs irbesartan as first line therapy in obese hypertensive patients: results of the HEBRO randomized controlled trial
Doctor P. Iliakis (Athens, GR)
Abstract Slides
Presentation thumbnail
Baxdrostat for treatment of uncontrolled and resistant hypertension: a meta-analysis and systematic review
Doctor A. Bortolotto (Sao Paulo, BR)
Abstract Slides

Access the full session

Session thumbnail
Aldosterone and hypertension

The Event

Event poster

ESC Congress 2026

28 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Primary hyperaldosteronism and phaeochromocytoma
31 August 2024
thumbnail
Congress Presentation
What is the treatment and management for patients with hypokalaemia? A critical review of the literature
13 June 2025
thumbnail
Congress Presentation
Role of urinary potassium to creatinine ratio for tailoring the type of diuretic regimen in patients with acute heart failure and diuretic resistance
23 May 2022
thumbnail
Congress Presentation
A safety and pharmacodynamic study of the highly selective aldosterone synthase inhibitor PB6440 in the cynomolgus monkey
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources